2019 Sales TOP10 Company and Drug Inventory

Over the past few years, Novartis and Pfizer have been fighting over meHowever, according to 2019, Roche topped the list, becoming the biggest winner in 2019Heavyweight drugs, including the multiple sclerosis drug Ocrelizumab and the PD-L1 inhibitor Tecentriq, have won big, taking the Swiss drugmaker overtwoing its rivalsIn addition, limited competition for biosimilars in major U.Smarkets has contributed to Roche's revenue growth, including cancer treatments Avastin (bevan monoantigen) and Heseltine (quto-bead monoantigen)sales of the top 10 companies, unit: $100 millionlast year, Novartis because of its anti-IL-17 monoclonal antibody Cosentyx (Secukinumab) performance in psoriasis, the company rose one place, ranked secondHowever, it is not clear how Novartis's future position will moveSome of its newer products, including gene therapy Zolgensma and heart failure product Entresto, should help make up for lost sales due to the expiration of patents for severe drugs, such as the multiple sclerosis drug Gilenya and the age-related macular degeneration (AMD) treatment, Lucentis (Ranibizumab)But the group has recently suffered a heavy fall in its share price because of safety concerns about the next-generation AMD drug, The BrolucizumabIf the product continues to be plagued by these safety issues, Beovu will not be able to meet its 2024 sales forecast of $1.47 billiontop 10 in sales, unit: $100 millionfourth place is MerckMerck's checkpoint inhibitor, Pembrolizumab, has driven much of Merck's progressAccording to EvaluatePharma, the PD-1 inhibitor is expected to become the industry's top-selling drug by 2024, with global sales estimated at $22.3 billionMerck recently announced a plan to split its women's health and biosimilars business into a new company focused on oncology, vaccines and animal health, which will reduce its rankingSales have been somewhat affected by Pfizer's spin-off of its consumer healthcare division and its existing drug businessSuch a change would maximize the impact of the breast cancer drug Ibrceand and the pneumococcal vaccine Prevnar 13Many believe the pharmaceutical giant's lack of innovation in research and development pipelines could hamper future polls, and recent management said it would take some time for the company to bring new gene therapy to market's ranking of the best-selling drugs for 2019 has also changed, with Keytruda ahead of Celgene's Revlimid in second placeKeytruda's sales have made impressive progress in 2018, thanks in large part to its dominance in non-small cell lung cancer and melanomaKeytruda has been a success, while Bristol-Myers Squibb's rival checkpoint inhibitor, Nivolumab, failed to capitalise on its debut and trailed Keytuda last year with annual sales of nearly $4billionBMS's anticoagulant, Apixaban, was in the top fiveWith so few future best sellers, it's no surprise that BMS bought Celgene for $74 billionThe move brings Revlimid's annual sales to more than $9 billion and will make BMS one of the five largest companies by 2020Humira remains the industry's best-selling drugAbbVie is working on a patent for the drug, meaning that humira biosimilars in the United States were first introduced in 2023But AbbVie's reliance on this old product is one reason why companies like Bristol are seeking acquisitions to update their product linesAbbVie will buy El Jian for $63 billion ($433.5 billion), not only reaping the rewards of ElJian's heavy-duty drug Botox, but also boosting AbbVie's sales ranking selling next yearTakeda is the top 10 newcomer after it bought Shire for $62 billion, the largest foreign takeover in Japanese historyoriginal title: 2019 sales top10 companies and pharmaceuticals